Digene
Home theHPVtest.com Newsroom Contact Us Sitemap
Search
Labs

Digene in the Lab
Hybrid Capture®2 Technology
The Digene HPV Test
CT/GC Testing
CMV Testing
Rapid Capture® System
Customer Service
Print This Page
Hybrid Capture® 2 Technology

Hybrid Capture 2 Technology Overview of Digene's Hybrid Capture® 2 Technology

Digene's proprietary Hybrid Capture® 2 (hc2) signal–amplification molecular technology serves as the platform for our gene–based tests. The Hybrid Capture® technology uses specific RNA probes, hybridization, antibody capture and signal amplification to allow rapid, standardized testing of the genetic material of infectious agents in virtually any laboratory setting. Hybrid Capture® 2 technology achieves clinically relevant levels of detection, using a user–friendly, cost–effective method. Reliable detection is achieved without the need for dedicated and isolated lab space, sophisticated laboratory expertise, or concern related to inhibition and contamination.

Digene's Hybrid Capture® 2 System Offers:

  • Same–day, objective results using a microplate test format.
  • High–throughput automation for handling increasing test volumes.
  • Sensitivity comparable to many other target–amplification technologies, without the complexity of these other test methods.
  • User–friendly technique that facilitates the production of consistent, reproducible results.
  • Minimal required specimen preparation, allowing samples to be processed quickly and efficiently.
  • Protection against cross–contamination problems that can occur with some target–amplification assays.

Hybrid Capture® tests are available to detect human papillomavirus (HPV), chlamydia trachomatis (CT), neisseria gonorrhea (GC), and cytomegalovirus (CMV); the latter is available in tube format only.

How Hybrid Capture® Technology Works:

The Hybrid Capture® System is a signal–amplification assay that uses a technique combining antibody capture and chemiluminescent signal detection. The basic steps of the Hybrid Capture® assay are outlined below:

Clinical specimens are prepared by adding a base solution, which disrupts the virus or bacteria and releases target DNA.

Hybrid Capture® 2 Technology

Presence or absence of target DNA is read from the results of the chemiluminescent reaction.

The Hybrid Capture® System is configured to adapt to virtually any workflow situation and is suitable for most laboratory staff skill levels. Both small and large specimen batches can be processed cost–effectively.

back to top

© 2007 Digene Corporation All Rights Reserved.   |   Legal   |   Privacy Statement   |   Feedback